2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Abion Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation Vabametkib, Lazertinib - Advanced Solid Tumors | Phase 2 | Recruiting | Abion Inc | 178 | 2023-01-17 | 2025-05-22 |
| To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers High-fat meal (over 900 kcal), ABN401 (investigational product) - Solid Tumor | Phase 1 | Completed | Abion Inc | 25 | 2022-01-04 | 2024-02-20 |
| To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation ABN401- Escalation Phase, ABN401- Expansion Phase - Advanced Solid Tumors | Phase 1 | Completed | Abion Inc | 24 | 2019-08-01 | 2025-01-06 |
lazertinib (1)
South Korea (3) · Australia (1) · Taiwan (1) · United States (1)